VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).

Authors:

Abstract
2533^ Background: Low prevalence of V600m in non-melanoma cancers requires a novel trial design to assess the activity of BRAF inhibitors. We undertook a histology-independent, “basket” study of VEM in BRAFV600m-positive cancers (NCT01524978). Six disease cohorts were prespecified, remaining tumors were enrolled to a 7th “all-comers” cohort. Here we present preliminary efficacy and safety data for the non-small cell lung cancer (NSCLC), cholangiocarcinoma (CLC), and Erdheim-Chester disease (ECD)/Langerhans cell histiocytosis (LCH) cohorts. Methods: Multicenter Simon 2-stage adaptive design in adult patients (pts; majority pretreated) with metastatic V600m-positive cancers receiving VEM (960 mg bid) until investigator (INV)-assessed disease progression (PD) or unacceptable toxicity. Primary endpoint is INV-assessed response rate (RR) at week 8 (RECIST v1.1). Secondary objectives include overall RR, clinical benefit rate, duration of response, progression-free survival, overall survival, and safety. Results...